β1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

被引:162
作者
Shain, Kenneth H. [1 ]
Yarde, Danielle N. [1 ]
Meads, Mark B. [1 ]
Huang, Mei [1 ]
Jove, Richard [1 ]
Hazlehurst, Lori A. [1 ]
Dalton, William S. [1 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Expt Therapeut & Oncol Sci, Tampa, FL 33612 USA
关键词
MEDIATED DRUG-RESISTANCE; MULTIPLE-MYELOMA; CAM-DR; CONFERS RESISTANCE; KINASE ACTIVATION; INDUCED APOPTOSIS; RECEPTOR COMPLEX; JANUS KINASE; U937; CELLS; DE-NOVO;
D O I
10.1158/0008-5472.CAN-08-2419
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The bone marrow microenvironmental components interleukin (IL)-6 and fibronectin (FN) individually influence the proliferation and survival of multiple myeloma (MM) cells; however, in vivo, these effectors most likely work together. We examined signaling events, cell cycle progression, and levels of drug response in MM cells either adhered to FN via 01 integrins, stimulated with IL-6, or treated with the two combined. Although G(1)-S cell cycle arrest associated with FN adhesion was overcome when IL-6 was added, the cell adhesion-mediated drug resistance (CAM-DR) was maintained in the presence of IL-6. Concomitant exposure of MM cells to IL-6 and FN adhesion revealed a dramatic increase in signal transducers and activators of transcription 3 (STAT3) phosphorylation, nuclear translocation, and DNA binding, compared with either IL-6 or FN adhesion alone in four MM cell lines. Importantly, this increase in STAT3 activation correlated with a novel association between STAT3 and gp130 in cells adhered to FN before stimulation with IL-6, relative to nonadherent cells. Taken together, these results suggest a mechanism by which collaborative signaling by beta 1 integrin and gp130 confers an increased survival advantage to MM cells. [Cancer Res 2009;69(3):1009-15]
引用
收藏
页码:1009 / 1015
页数:7
相关论文
共 39 条
[1]   Janus kinase (Jak) subcellular localization revisited -: The exclusive membrane localization of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak•receptor complex to be equivalent to a receptor tyrosine kinase [J].
Behrmann, I ;
Smyczek, T ;
Heinrich, PC ;
Schmitz-Van de Leur, H ;
Komyod, W ;
Giese, B ;
Müller-Newen, G ;
Haan, S ;
Haan, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (34) :35486-35493
[2]   Chromosome translocations in multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
ONCOGENE, 2001, 20 (40) :5611-5622
[3]   A comparison of normalization methods for high density oligonucleotide array data based on variance and bias [J].
Bolstad, BM ;
Irizarry, RA ;
Åstrand, M ;
Speed, TP .
BIOINFORMATICS, 2003, 19 (02) :185-193
[4]   Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation [J].
Brocke-Heidrich, K ;
Kretzschmar, AK ;
Pfeifer, G ;
Henze, C ;
Löffler, D ;
Koczan, D ;
Thiesen, HJ ;
Burger, R ;
Gramatzki, M ;
Horn, F .
BLOOD, 2004, 103 (01) :242-251
[5]   Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells [J].
Catlett-Falcone, R ;
Landowski, TH ;
Oshiro, MM ;
Turkson, J ;
Levitzki, A ;
Savino, R ;
Ciliberto, G ;
Moscinski, L ;
Fernández-Luna, JL ;
Nuñez, G ;
Dalton, WS ;
Jove, R .
IMMUNITY, 1999, 10 (01) :105-115
[6]   Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells [J].
Chauhan, D ;
Kharbanda, S ;
Ogata, A ;
Urashima, M ;
Teoh, G ;
Robertson, M ;
Kufe, DW ;
Anderson, KC .
BLOOD, 1997, 89 (01) :227-234
[7]  
CHAUHAN D, 1995, STEM CELLS, V13, P35
[8]  
Chauhan D, 2000, J BIOL CHEM, V275, P27845
[9]   RACK1 regulates integrin-mediated adhesion, protrusion, and chemotactic cell migration via its Src-binding site [J].
Cox, EA ;
Bennin, D ;
Doan, AT ;
O'Toole, T ;
Huttenlocher, A .
MOLECULAR BIOLOGY OF THE CELL, 2003, 14 (02) :658-669
[10]   Integrin-mediated drug resistance in multiple myeloma [J].
Damiano, JS ;
Dalton, WS .
LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) :71-81